You are now leaving Abacavir HSR Support. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third parties.
Patients must be made aware of the possibility of a hypersensitivity reaction to abacavir that may result in a life-threatening reaction or death, and that the risk of a hypersensitivity reaction is increased if they are HLA-B*5701 positive.
Patients must also be informed that a HLA-B*5701 negative patient can also experience an abacavir hypersensitivity reaction. Therefore ANY patient who develops signs or symptoms consistent with a possible hypersensitivity reaction to abacavir MUST CONTACT THEIR DOCTOR IMMEDIATELY.
Patients who are hypersensitive to abacavir should be reminded that they must never take Ziagen or any other medicinal product containing abacavir (e.g. Kivexa, Trizivir, Triumeq) again, regardless of their HLA-B*5701 status.
Have a plan to communicate in the event of a reaction
Patients who have stopped abacavir for any reason, and particularly due to adverse reaction or illness, must be advised to contact their doctor before restarting.
Each patient should be reminded to read the Package Leaflet included in the abacavir pack. They should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.
In order to avoid restarting abacavir, patients who have experienced a hypersensitivity reaction should be asked to return the remaining abacavir tablets or oral solution to the pharmacy.
- Have your patients read the Patient Information Leaflet?
- Have your patients read the Patient Alert Card? Your patients can find the latest Alert Card in the product pack.
* ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third parties.